EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Potent Antitumor Efficacy of a Novel ALPPL2/ALPP-Targeting Antibody-Drug Conjugate in Preclinical Models

Lili Wang, Xiaoping Zhang, Guohong Liu, Xiaoli He, Jianing Liu, Shuya Ji, Mingyang Li, Yidan Xu, Xiao Wang, Yuanhao Li, Jinliang Yang

Antibody Therapeutics · 2026-11-08

DOI: 10.1093/abt/tbag055 ↗
AbstractBibliografische Angaben

Abstract

Abstract: Background The antitumor efficacy of antibody-drug conjugates (ADCs) is primarily determined by the tissue-specific distribution of target antigens. Placental alkaline phosphatase-like protein 2 (ALPPL2) and placental alkaline phosphatase (ALPP) are highly homologous and aberrantly overexpressed in multiple human malignancies, while minimally expressed in most normal adult tissues, rendering them ideal targets for tumor-targeted therapeutics. However, ALPPL2/ALPP-targeted therapeutics remain in their infancy, with no clinically approved agents, presenting a significant translational opportunity. Methods Antibodies were prepared via hybridoma technology. Their binding specificity, affinity, cross-species reactivity and internalization were characterized using flow cytometry and biolayer interferometry (BLI). Competitive epitope binning was applied to delineate the epitope diversity. Lead candidates were conjugated with monomethyl auristatin E (MMAE) to construct ALPPL2 ADCs, and their antitumor potency was systematically evaluated in vitro and in vivo across various tumor models. Results A panel of chimeric antibodies featuring high affinity, high specificity, and rapid internalization was generated and grouped into discrete epitope bins. The lead candidate AL71 shares substantial but non-identical epitope overlap with the benchmark SGN-ALPV and displays improved cross-reactivity against cynomolgus monkey ALPP. Critically, AL71-ADC surpasses SGN-ALPV, demonstrating enhanced in vitro cytotoxicity across multiple tumor cell models and potent in vivo antitumor activity in xenograft models. Conclusions AL71-ADC generated herein exhibits superior preclinical antitumor efficacy and cross-species reactivity relative to benchmark SGN-ALPV. Given the tumor-restricted expression of ALPPL2/ALPP alongside unmet clinical demands, AL71-ADC represents a promising therapeutic candidate for the treatment of ALPPL2/ALPP-positive malignancies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →